MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
AIDS Healthcare Foundation (AHF) has modernized its contract management processes using CloudMoyo’s generative AI-powered IntelliDoc Analyze (CDA) platform. CloudMoyo is a global AI-first consulting solutions firm. The platform is designed to improve efficiency and accelerate document analysis and data extraction. The solution uses AI to analyze contracts, extract key terms, identify obligations and flag potential issues, helping AHF manage agreements more consistently as it operates across multiple regions and regulatory environments. The platform enables faster review cycles while improving visibility into contractual commitments.
The move reflects growing adoption of generative AI for document-intensive business functions. By applying AI-driven analysis, AHF aims to reduce manual effort and support better governance without expanding administrative overhead. For IT and operations leaders, the deployment highlights how generative AI is increasingly being applied to back-office modernization, even in highly regulated and mission-driven organizations. This launch shows the move towards digital transformation in healthcare sectors, leveraging AI, data solutions and Agentic AI.
Posted by MedCloudInsider Editors on 01/20/20260 comments
Katalyze AI, builder of Agentic AI systems for pharmaceutical manufacturing, has launched Katalyst, an agentic AI platform designed specifically for pharmaceutical manufacturing operations. The AI agent is built to help manufacturing teams accelerate scientific decision-making and operate with grounded insights for production data. The platform is designed to operate within existing manufacturing systems, supporting use cases such as deviation analysis, root-cause identification and continuous process optimization while respecting regulatory constraints. Katalyst connects to existing operational systems to combine statistical analysis, advanced data visualizations with scientifically grounded reasoning towards improved production yields.
The launch comes as pharmaceutical manufacturers face increasing pressure to modernize operations without compromising compliance. For operations and IT leaders in pharma, Katalyst reflects a growing trend toward embedding AI directly into manufacturing workflows to improve reliability, accelerate decision-making and support more resilient supply chains.
Posted by MedCloudInsider Editors on 01/20/20260 comments
MediKarma, a leader in Agentic AI for healthcare, has launched what it describes as healthcare’s first Agentic AI Licensing Program, designed to give providers and partners access to pre-validated AI agents focused on disease management. The model allows healthcare organizations to license individual agents tailored to specific conditions, rather than building or training systems from scratch. MediKarma's agents are designed to support care coordination, patient engagement and longitudinal disease monitoring while operating within defined clinical and governance boundaries.
The announcement comes as healthcare systems explore how to operationalize AI beyond pilots while maintaining safety, compliance, and clinical trust. Members can choose between two agents: Jack AI, a universal enterprise engine that is designed to solve the industry's data fragmentation issue or Jill AI, which provides health-related agents on demand for distinct wellness issues. MediKarma’s approach reflects growing interest in treating AI agents as regulated digital assets, which could enable faster adoption while reducing development risk for providers navigating complex regulatory environments towards the next generation of digital health.
Posted by MedCloudInsider Editors on 01/12/20260 comments
Impilo, the creator of a hybrid healthcare delivery operating system, has introduced TaylorAI, a digital health concierge agent built to help patients navigate setting up monitoring devices and assist with troubleshooting. The AI agent is designed to answer common questions, assist with scheduling, guide patients through how to use their monitoring devices and explain to patients exactly what is happening in real-time.
The launch comes as healthcare organizations continue to invest in AI tools that address administrative friction rather than direct clinical decision-making. For health systems, agentic AI assistants like TaylorAI represent a step toward more continuous, personalized patient interactions while helping organizations manage staffing constraints and rising service expectations. The launch supports Impilo's aim of supporting patients throughout their care journey with a smooth, seamless process.
Posted by MedCloudInsider Editors on 01/12/20260 comments
Function, a medical and health company on a mission to empower humanity to reach 100 years, has launched the Function Connector, an integration with Claude, the large language model developed by Anthropic. The integration allows members to authorize Claude to access lab results and to provide guided health advice that is based on these results. Function said the goal is to make members understand their health-related matters in a simple way that can guide smarter, healthier choices.
The Function Connector provides tools that make accessing health data simple. These include the option of an overview of lab results, biomarker category summaries and the health protocol tool aimed at nutrition. It uses secure authentication and encryption, ensuring that your data is only at a summary level, protecting personal information from being used as training data. The connector for Claude is available to members of Function.
Posted by MedCloudInsider Editors on 01/12/20260 comments
Recent research reveals that Biotronik Neuro's remote monitoring with real-time visibility into spinal cord stimulation (SCS) usage can support a more effective, long-term approach to managing implanted neurostimulation devices. Biotronik is a leading medical device company aimed at developing improvements for heart and blood vessel diseases. The research examined how continuous data on stimulation patterns and patient engagement can help clinicians better understand therapy adherence, optimize programming and identify issues earlier than traditional follow-up methods. Researchers claim that the approach addresses a long-standing gap in post-implant care, where limited visibility has made it difficult to assess how devices are actually used outside the clinic.
Spinal cord stimulation is widely used for chronic pain, but outcomes vary significantly over time. The study’s findings suggest that real-time utilization data could become a foundation for more proactive device management, aligning neuromodulation with broader trends toward connected medical devices and continuous care models in chronic disease treatment. Other key findings show that 96.8 percent of patients were actively using therapy with less than 1 percent of patients classified as virtual explants.
Posted by MedCloudInsider Editors on 01/05/20260 comments
Mira Precision Health, specialists in precision medicine diagnostics, has announced the U.S. launch of ToxNav Advantage, an AI-based clinical decision support platform, at the 2026 ASCO Gastrointestinal Cancers Symposium. The software is designed to help oncologists assess and manage treatment-related toxicity risk by analyzing patient-specific data alongside therapy characteristics. Mira intends for ToxNav Advantage to support more informed treatment planning, particularly for gastrointestinal cancers where adverse effects can limit dose intensity or lead to early discontinuation.
The launch comes as oncology teams face growing complexity in balancing efficacy and tolerability across expanding treatment options. Key features include comprehensive analysis of gene variants, rapid turnaround time for actionable results and clear optimized reports that are clinician-friendly with actionable insights that prevent life-threatening toxicities. By emphasizing prospective toxicity insights, Mira’s approach reflects broader interest in using AI to support individualized care planning. For health systems, tools that reduce avoidable adverse events may also help improve quality metrics and resource utilization.
Posted by MedCloudInsider Editors on 01/05/20260 comments
The Veterans Health Venture Studio (VHVS), an engine designed to develop the pipeline of innovation, expands its Make-a-thon program, an innovation initiative that pairs VA clinicians, engineers, designers and veterans to rapidly develop solutions to unmet needs in health care delivery and daily living. The Make-a-thon is supported by the VA's Office of Healthcare, The American Legion and Microsoft. At its core, the program is powered by Microsoft with expert innovative training, experts and mentorship. The program focuses on hands-on collaboration, enabling teams to prototype assistive devices, clinical tools, and workflow improvements in short, intensive sprints. VA officials want the approach to help translate frontline insights into practical solutions more quickly than traditional procurement or research pathways.
The Make-a-thon model reflects a broader trend across healthcare systems toward co-design and clinician-led innovation. The VA’s national scale and direct access to veteran populations give it a distinct role. The aim of the program is designed to strengthen healthcare innovation and advance functional prototype projects with VA systems. For veterans, the initiative emphasizes functional outcomes—mobility, independence, and quality of life—while offering the VA a repeatable framework for advancing innovation aligned with real operational needs.
Posted by MedCloudInsider Editors on 01/05/20260 comments
Link Cell Therapies, a biotechnology oncology cell therapy company, has officially launched with the mission of accelerating the development of next-generation CAR-T therapies targeting both liquid and solid tumours. The company plans to apply innovations in cell engineering, tumor microenvironment modulation, and safety switches to overcome longstanding challenges that have limited CAR-T efficacy in solid malignancies. Link says its initial programs will advance through preclinical validation with IND-enabling goals, targeting tumor antigens with broad expression profiles and engineered features designed to improve persistence and reduce off-target toxicity.
Link’s strategy of combining advanced engineering and adaptive safety mechanisms aligns with competitors' efforts to target solid tumor niches. For developers and clinicians, the company’s entry underscores the evolving landscape of cellular therapies where addressing solid malignancies remains a key frontier. The LNK001 program is aimed at treating renal cell carcinoma with two unique antigens for RCC tumors. The unique technology could enable the development of multiple treatments for patients.
Posted by MedCloudInsider Editors on 12/15/20250 comments
BioTec, a specialized bio company, has introduced two new sulfur-based products designed for industrial and agricultural markets, expanding its portfolio with materials intended to improve performance in applications such as advanced coatings and soil treatment. The company highlighted its new offerings at recent domestic and international exhibitions, emphasizing its formulation technology and its potential to meet evolving customer specifications. BioTec says the products leverage its sulfur-derivative expertise and production infrastructure to deliver consistent quality and scalable supply.
The launches come as demand grows for specialty chemical solutions that balance performance with regulatory and sustainability requirements. BioTec’s focus on exhibition showcases signals its intention to broaden market awareness and customer engagement as it seeks to convert interest into commercial uptake across its target sectors.
Posted by MedCloudInsider Editors on 12/15/20250 comments
Astrin Biosciences, a cancer intelligence company, has established a scientific advisory board to support the development of its AI-enabled proteomics platform for early cancer detection. The new board includes clinicians and researchers with backgrounds in oncology, biomarker discovery and machine learning, who will advise on study design, validation strategies and clinical translation. The development of the board comes post the launch of Astrin's Certitude Breast, a non-imaging screening test that can detect breast cancer in early stages. Astrin claims expert input is critical as it advances toward larger trials and potential regulatory pathways.
Interest in proteomic diagnostics has accelerated as researchers look beyond genomics for earlier and more accurate detection tools. For health systems seeking noninvasive screening options, platforms that leverage AI to interpret complex protein data could offer a complementary route to earlier detection and improved outcomes.
Posted by MedCloudInsider Editors on 12/08/20250 comments
Inductive Bio, an AI drug discovery partner, has received an award of up to $21 million to advance AI-driven toxicity models intended to improve drug safety assessment and reduce downstream development risk. The company will work with leading academic and biopharmaceutical partners to generate datasets, validate predictive models and evaluate how AI can better characterize off-target effects early in the R&D cycle. Inductive Bio aims to use the initiative to address persistent gaps in preclinical toxicity screening, where conventional models often fail to capture complex biological interactions that later lead to trial delays or program termination.
Safety-related attrition remains one of the most costly challenges in drug development. Inductive Bio’s effort, backed by a multi-institution consortium, reflects growing momentum toward shared datasets and collaborative validation frameworks. For biopharma R&D teams under pressure to cut costs and accelerate timelines, more accurate toxicity forecasting could materially reshape portfolio decision-making.
Posted by MedCloudInsider Editors on 12/08/20250 comments